Terms: = Endocrine gland cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
3690 results:
1. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid cancer.
Fu G; Chazen RS; MacMillan C; Witterick IJ
JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
[TBL] [Abstract] [Full Text] [Related]
2.
Prabhash K; Saldanha E; Patil V; Bal M; Reddy P S; Sanjeev A; Kumar R; Poojary D; Noronha V; Menon N; Mittal N; Trivedi V; Nambiar K; Mishra R; Tanwar N; Malhotra R; Pange P; Gupta V; Veldore VH; Chougule A; Chaturvedi P; Dutt A; Chandrani P
JCO Precis Oncol; 2024 May; 8():e2300622. PubMed ID: 38754058
[TBL] [Abstract] [Full Text] [Related]
3. Exploiting the ferroaddiction of pancreatic cancer cells using Fe-doped nanoparticles.
Lomphithak T; Sae-Fung A; Sprio S; Tampieri A; Jitkaew S; Fadeel B
Nanomedicine; 2024 Jan; 55():102714. PubMed ID: 38738528
[TBL] [Abstract] [Full Text] [Related]
4. Cytokine CCL9 Mediates Oncogenic kras-Induced Pancreatic Acinar-to-Ductal Metaplasia by Promoting Reactive Oxygen Species and Metalloproteinases.
Liou GY; Byrd CJ; Storz P; Messex JK
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731942
[TBL] [Abstract] [Full Text] [Related]
5. Keratin 17 modulates the immune topography of pancreatic cancer.
Delgado-Coka L; Horowitz M; Torrente-Goncalves M; Roa-Peña L; Leiton CV; Hasan M; Babu S; Fassler D; Oentoro J; Bai JK; Petricoin EF; Matrisian LM; Blais EM; Marchenko N; Allard FD; Jiang W; Larson B; Hendifar A; Chen C; Abousamra S; Samaras D; Kurc T; Saltz J; Escobar-Hoyos LF; Shroyer KR
J Transl Med; 2024 May; 22(1):443. PubMed ID: 38730319
[TBL] [Abstract] [Full Text] [Related]
6. The Effect of Intratumor Heterogeneity in Pancreatic Ductal Adenocarcinoma Progression and Treatment.
Saleh O; Shihadeh H; Yousef A; Erekat H; Abdallh F; Al-Leimon A; Elsalhy R; Altiti A; Dajani M; AlBarakat MM
Pancreas; 2024 May; 53(5):e450-e465. PubMed ID: 38728212
[TBL] [Abstract] [Full Text] [Related]
7. Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets.
Faber EB; Krause HB; Amin K; Walker P; Hosein PJ; Shields AF; Lenz HJ; Prakash A; Goel S; Oberley M; Malleo G; Luchini C; Hwang J; Florou V; Garrido-Laguna I; Lou E
JCO Precis Oncol; 2024 May; 8():e2300595. PubMed ID: 38723231
[TBL] [Abstract] [Full Text] [Related]
8. Neoadjuvant management of locally advanced pancreatic ductal adenocarcinoma - Heading towards a promising change in treatment paradigm.
Mahmood U; Carrier E; Khan K
Cancer Treat Rev; 2024 Jun; 127():102750. PubMed ID: 38703592
[TBL] [Abstract] [Full Text] [Related]
9. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
[TBL] [Abstract] [Full Text] [Related]
10. 3D genomic mapping reveals multifocality of human pancreatic precancers.
Braxton AM; Kiemen AL; Grahn MP; Forjaz A; Parksong J; Mahesh Babu J; Lai J; Zheng L; Niknafs N; Jiang L; Cheng H; Song Q; Reichel R; Graham S; Damanakis AI; Fischer CG; Mou S; Metz C; Granger J; Liu XD; Bachmann N; Zhu Y; Liu Y; Almagro-Pérez C; Jiang AC; Yoo J; Kim B; Du S; Foster E; Hsu JY; Rivera PA; Chu LC; Liu F; Fishman EK; Yuille A; Roberts NJ; Thompson ED; Scharpf RB; Cornish TC; Jiao Y; Karchin R; Hruban RH; Wu PH; Wirtz D; Wood LD
Nature; 2024 May; 629(8012):679-687. PubMed ID: 38693266
[TBL] [Abstract] [Full Text] [Related]
11. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract] [Full Text] [Related]
12. Targeting kras in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
13. The pRb/RBL2-E2F1/4-GCN5 axis regulates cancer stem cell formation and G0 phase entry/exit by paracrine mechanisms.
Chang CH; Liu F; Militi S; Hester S; Nibhani R; Deng S; Dunford J; Rendek A; Soonawalla Z; Fischer R; Oppermann U; Pauklin S
Nat Commun; 2024 Apr; 15(1):3580. PubMed ID: 38678032
[TBL] [Abstract] [Full Text] [Related]
14. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing.
Lahusen A; Cai J; Schirmbeck R; Wellstein A; Kleger A; Seufferlein T; Eiseler T; Lin YN
Sci Rep; 2024 Apr; 14(1):9377. PubMed ID: 38654067
[TBL] [Abstract] [Full Text] [Related]
15. Targeting kras in cancer.
Singhal A; Li BT; O'Reilly EM
Nat Med; 2024 Apr; 30(4):969-983. PubMed ID: 38637634
[TBL] [Abstract] [Full Text] [Related]
16. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating kras-c-RAF dependent PDAC.
Cooke SF; Wright TA; Sin YY; Ling J; Kyurkchieva E; Phanthaphol N; Mcskimming T; Herbert K; Rebus S; Biankin AV; Chang DK; Baillie GS; Blair CM
Sci Rep; 2024 Apr; 14(1):8998. PubMed ID: 38637546
[TBL] [Abstract] [Full Text] [Related]
17. A glycolytic metabolite bypasses "two-hit" tumor suppression by BRCA2.
Kong LR; Gupta K; Wu AJ; Perera D; Ivanyi-Nagy R; Ahmed SM; Tan TZ; Tan SL; Fuddin A; Sundaramoorthy E; Goh GS; Wong RTX; Costa ASH; Oddy C; Wong H; Patro CPK; Kho YS; Huang XZ; Choo J; Shehata M; Lee SC; Goh BC; Frezza C; Pitt JJ; Venkitaraman AR
Cell; 2024 Apr; 187(9):2269-2287.e16. PubMed ID: 38608703
[TBL] [Abstract] [Full Text] [Related]
18. Genetic Signature of Human Pancreatic cancer and Personalized Targeting.
Reshkin SJ; Cardone RA; Koltai T
Cells; 2024 Mar; 13(7):. PubMed ID: 38607041
[TBL] [Abstract] [Full Text] [Related]
19. Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer.
Fu J; Ling J; Li CF; Tsai CL; Yin W; Hou J; Chen P; Cao Y; Kang Y; Sun Y; Xia X; Jiang Z; Furukawa K; Lu Y; Wu M; Huang Q; Yao J; Hawke DH; Pan BF; Zhao J; Huang J; Wang H; Bahassi EIM; Stambrook PJ; Huang P; Fleming JB; Maitra A; Tainer JA; Hung MC; Lin C; Chiao PJ
Nat Commun; 2024 Apr; 15(1):3149. PubMed ID: 38605037
[TBL] [Abstract] [Full Text] [Related]
20. RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers.
Wolfe AR; Feng H; Zuniga O; Rodrigues H; Eldridge DE; Yang L; Shen C; Williams TM
Cancer Lett; 2024 Jun; 591():216873. PubMed ID: 38604313
[TBL] [Abstract] [Full Text] [Related]
[Next]